1 sure, while change in CDVA was the secondary
outcome measure.
2 first year of clinical position was the main
outcome measure.
3 upillary reflex distance was the most common
outcome measure.
4 ion volume, V(T), is frequently the reported
outcome measure.
5 ther RRD surgery within 90 days, is the main
outcome measure.
6 develop the final pCMT-QOL patient-reported
outcome measure.
7 ading and at 2 years by the Pediatric Stroke
Outcome Measure.
8 Final visual acuity is the secondary
outcome measure.
9 uroimaging, or functional neuroimaging as an
outcome measure.
10 d total volume of distribution (V(T)) as the
outcome measure.
11 LoS (post OCS, PCS, UCS) was the
outcome measure.
12 re marginal improvements with some secondary
outcome measures.
13 deuterated water) MPS responses, the primary
outcome measures.
14 ing longitudinal experiments and multiplexed
outcome measures.
15 associated with worse oral health across all
outcome measures.
16 termine the impact of GBA1 variants on these
outcome measures.
17 e in forthcoming clinical trials as endpoint/
outcome measures.
18 to the pathology of the disease and as trial
outcome measures.
19 ty and pure tone audiograms are not suitable
outcome measures.
20 highest concavity predicted the prospective
outcome measures.
21 Hospital LOS and mortality were used as
outcome measures.
22 for broad measures, and two patient-reported
outcome measures.
23 There are few well-validated FND-specific
outcome measures.
24 e assessed at baseline and study endpoint as
outcome measures.
25 fforts were identified and invited to submit
outcome measures.
26 e PET measures were correlated with clinical
outcome measures.
27 d reports were used to determine exploratory
outcome measures.
28 4, and we discuss the importance of clinical
outcome measures.
29 arger randomized trials with more definitive
outcome measures.
30 st follow-up (up to 1 year) were the primary
outcome measures.
31 d costs, and to investigate patient-reported
outcome measures.
32 elations between preoperative BCVA and above
outcome measures.
33 pression, and CEC density served as the main
outcome measures.
34 acuity, complications, and patient-reported
outcomes measures.
35 The coprimary
outcomes, measured 5 minutes post-FC administration were
36 observation procedure(s): chart review; main
outcome measures:
anatomy, intraocular pressure (IOP), b
37 2 AS populations, one severe AS (n=572) with
outcome measures and one with mixed severity (n=67).
38 Future research should focus on PG-specific
outcome measures and PG quality-of-life studies.
39 Bootstrapping, out-of-model
outcome measures and supervised machine learning were ea
40 conducted to identify existing FND-specific
outcome measures and the most common measurement domains
41 hodological issues, including differences in
outcome measures and their definitions, lack of pre-spec
42 The lack of consistent use of the same
outcome measures and validated GAS-specific instruments
43 tio correlate with invasive hemodynamics and
outcomes measures,
and EI can accurately define those wi
44 VTE
outcome measures are invalidated for interhospital compa
45 Uniform reported
outcome measures are needed to draw more definitive conc
46 plained observed variation, using functional
outcome measures as proxies for severity.
47 reated orbit was observed in any of the main
outcome measures at 6 months.
48 The primary
outcome, measured at 24 months of corrected age, was dea
49 ediation analysis, because the mediators and
outcomes measured at a given time point can act as confo
50 ntered on European-ancestry participants and
outcomes measured at a single time-point, so key priorit
51 udy-Access to Transplantation and Transplant
Outcome Measures (
ATTOM).
52 per-occlusion and 24 h MRI, neurofunctional
outcome measured by neuroscores.
53 here was no association with stroke survivor
outcome measured by the modified Rankin Scale.
54 utcomes were a range of infant and caregiver
outcomes measured by Manchester Assessment of Caregiver-
55 The primary
outcome measured change in %CD38+HLA-DR+ CD8+ T cells.
56 al features and outcomes were gathered. Main
Outcome Measures:
Clinical setting, surgical technique,
57 Comprehensive patient-reported
outcome measures collected at serial time points are now
58 To propose a novel composite
outcome measure (
COM) for periodontal regenerative treat
59 Outcome measures consisted of a composite end point of d
60 Outcome measures evaluated long-term functional, physica
61 toperative over IS or high IPV and long-term
outcome measures following LT.
62 A patient-reported
outcome measure for chemotherapy-induced peripheral neur
63 ACDiT may be considered a meaningful
outcome measure for comparing strategies for acute diver
64 to construct and validate a patient-reported
outcome measure for screening and monitoring vision-rela
65 The main
outcome measure for the clinical study was insulin cessa
66 an durations and SUVR-1 provide quantitative
outcome measures for (11)C-(+)-PHNO, a dopamine D(3) rec
67 certainty intervals (UIs) around our primary
outcome measures for each intervention scenario.
68 We aimed to identify existing
outcome measures for functional neurological disorder (F
69 acebo, on exploratory and minimally invasive
outcome measures for moderate to severe dry eye disease.
70 ieve harmonization of registry-based quality
outcome measures for TEVAR.
71 Main
outcome measures for the economic evaluation were total
72 Healthcare Research and Quality's supported
Outcome Measures Framework.
73 Healthcare Research and Quality's supported
Outcome Measures Framework.
74 g two international meetings of the FND-Core
Outcome Measures group.
75 ays (VFDs) are a commonly reported composite
outcome measure in acute respiratory distress syndrome t
76 est grid using microperimetry is a sensitive
outcome measure in clinical trials investigating new tre
77 of disease progression and as a therapeutic
outcome measure in response to treatment.
78 Periodontal
outcome measures in 2011 were the number of teeth with d
79 post-test declarative knowledge were used as
outcome measures in 36 individuals who participated in t
80 n secondary efficacy and safety/tolerability
outcome measures in Asian patients were also similar to
81 olled in the SubPopulations and InteRmediate
Outcome Measures In COPD (SPIROMICS) bronchoscopy sub-st
82 of COPD: the Subpopulations and Intermediate
Outcome Measures in COPD Study (SPIROMICS), which involv
83 ectroscopy are increasingly considered to be
outcome measures in Duchenne muscular dystrophy (DMD) cl
84 rium-specific outcome domains within 19 Core
Outcome Measures in Effectiveness Trials taxonomy catego
85 We categorized reported outcomes using Core
Outcome Measures in Effectiveness Trials taxonomy.
86 mes, as anticipated; the number of secondary
outcome measures in our trial, which may increase the ri
87 ach for establishing benchmarks for relevant
outcome measures in surgery.
88 following PRISMA guidelines to identify all
outcomes measures in GAS cohorts, including PCOs, compli
89 Secondary
outcome measures include task-based fMRI (RISE task), mi
90 Outcome measures included 3-week and 3-month visual acui
91 Outcome measures included allergic reactions (ie gastroi
92 Secondary
outcome measures included device-related adverse events
93 Secondary
outcome measures included discontinuation of medications
94 Secondary
outcome measures included evaluating readability, access
95 Secondary
outcome measures included exposure between binary and ca
96 Secondary
outcome measures included individual components of the p
97 Outcome measures included intraocular pressure (IOP) and
98 The main
outcome measures included IOL decentration and PCO.
99 Secondary
outcome measures included IOP, glaucoma medical therapy,
100 Our primary
outcome measures included IVCM and histopathologic findi
101 Primary
outcome measures included lagophthalmos on blink, gentle
102 Secondary
outcome measures included mean change from baseline in G
103 Secondary
outcome measures included need for subsequent interventi
104 The main
outcome measures included NK healing, corneal sensitivit
105 Secondary
outcome measures included OCT measurements such as centr
106 Outcome measures included pancreatic lipase levels, the
107 Outcome measures included patient mortality; hospital re
108 Outcome measures included rates of survival to hospital
109 Secondary
outcome measures included the changes in cup volume, dis
110 Our main
outcome measures included the cumulative incidence of RC
111 Primary
outcome measures included the incidence of all RAO, incl
112 Secondary
outcome measures included the number of antiglaucoma med
113 Secondary
outcome measures included the number of IOP-lowering med
114 The primary
outcome measures included the size of the epithelial def
115 Outcome measures included time from diagnosis to papille
116 Main
outcome measures included visual acuity, Foster stages,
117 Outcomes measured included varicella and HZ incidences,
118 reoperative and postoperative clinical data,
outcome measures including intraocular pressure (IOP), u
119 or meaningful benefits were observed for any
outcome measure,
including mood and cognitive measures.
120 tors of success and postoperative changes in
outcome measures,
including IOP and medication use, were
121 rative, not research, purposes, and clinical
outcome measures,
including retention and viral suppress
122 The pCMT-QOL patient-reported
outcome measure is a reliable, valid, and sensitive meas
123 Main
outcome measure is the recovery of efferent dysfunction
124 these drugs in terms of clinical and imaging
outcome measures is welcomed, these therapeutics are ass
125 Thus, at present, we recommend that existing
outcome measures,
known to be reliable, valid and respon
126 al non-differential misclassification of the
outcome measures leading to an attenuation of observed a
127 and observational treatment studies (k=40),
outcome measures most often assessed core FND symptom ch
128 The primary
outcome measure,
MPA concentration (<0.1 ng/mL) at week
129 h groups showed improvement in the secondary
outcome measure of functional cognition, with no signifi
130 roduce the statistically significant primary
outcome measure of the clinical trial.
131 The primary
outcome measure of tic severity was the Yale Global Tic
132 = 60]), adverse events, and patient-reported
outcome measures of health status, health-related qualit
133 gnificant additional benefits in the primary
outcome measures of muscle mass, strength, or cognitive
134 boratory, and prognostic characteristics and
outcome measures of these patients.
135 dex) or EASI-75, as well as patient-reported
outcomes measures (
Patient-Oriented Eczema Measure, Derm
136 dies to develop a pediatric CMT-specific QOL
outcome measure (
pCMT-QOL).
137 correlated with invasive hemodynamics and PH
outcome measures (
PH-related hospitalization, functional
138 Main
outcome measures Preference and willingness to pay estim
139 a novel ventral hernia (VH) patient-reported
outcomes measure (
PROM).
140 Patient-reported
outcome measures (
PROMs) are commonly used to estimate d
141 ents and vocalisations should be the primary
outcome measure,
rather than subjective scales or diarie
142 med to develop a minimum set of standardized
outcome measures relevant to both patients and clinician
143 Information on the exposure and
outcome measures,
results, and acknowledged limitations
144 MAIN
OUTCOME MEASURE(
S): Population-based CT/MR imaging rates
145 Home time is a patient-centered
outcome measure that accounts for rehospitalization, mor
146 Failure to cure is a composite
outcome measure that could be used for hospital comparis
147 ction effect was significant for the primary
outcome measure,
the HAM-D-6.
148 , and the optimisation was based on a single
outcome measure,
therefore this study should be used to
149 etrically validated 14-item patient-reported
outcome measure to be used as a psychosocial screening a
150 hologic factors and may serve as a surrogate
outcome measure to monitor GA progression in future stud
151 RLN injury provides several novel functional
outcome measures to increase the translational potential
152 es were significant and favorable for 4 of 5
outcomes measured under RCT (eg, reduced opioid use; odd
153 uture work needs to more rigorously validate
outcome measures used in this population.
154 The primary
outcome measure was 90-day mortality, and main secondary
155 The primary
outcome measure was a change in maximum keratometry (Kma
156 The primary
outcome measure was a comparison of the DISCERN and HONc
157 The primary
outcome measure was a positive reverse transcription-pol
158 The primary
outcome measure was adverse events in the period between
159 Secondary
outcome measure was annual health care use and costs by
160 The main
outcome measure was any albuminuria including both micro
161 The primary
outcome measure was aseptic revision, defined as any reo
162 Our primary
outcome measure was association between age, type and se
163 The primary
outcome measure was association between binary PPS expos
164 The secondary
outcome measure was before versus after change in the ED
165 Primary
outcome measure was best corrected LogMAR visual acuity
166 The primary
outcome measure was BSCVA at 12 months after surgery.
167 The primary
outcome measure was change in best corrected visual acui
168 The primary
outcome measure was change in the Hamilton Depression Ra
169 The primary
outcome measure was change in the mean best corrected vi
170 The primary
outcome measure was change in walk time on a treadmill w
171 The primary
outcome measure was clinical relapse, defined as any ser
172 The primary
outcome measure was collected in 98% of patients.
173 The primary
outcome measure was correction of head tilt.
174 The primary
outcome measure was deep surgical site infection at 30 d
175 The primary
outcome measure was depression symptom severity as asses
176 Main
outcome measure was final BCVA.
177 The primary
outcome measure was freedom from distant metastases, des
178 The main
outcome measure was freedom from recurrent biliary obstr
179 The secondary
outcome measure was functional cognition, assessed by th
180 The primary
outcome measure was global cognitive performance, assess
181 The main
outcome measure was globe salvage rate.
182 The primary
outcome measure was HR.
183 The primary
outcome measure was hydrocortisone-induced DeltaV(T) cal
184 The primary
outcome measure was in-hospital major adverse cardiac ev
185 Our primary
outcome measure was in-hospital mortality.
186 The primary
outcome measure was incidence of postoperative infectiou
187 Primary
outcome measure was intraocular pressure (IOP).
188 The primary
outcome measure was left ventricular ejection fraction a
189 Main
outcome measure was median percent adherence over 3 mont
190 Primary
outcome measure was patient utilization of outpatient op
191 The main
outcome measure was post-discharge opioid consumption, a
192 The main
outcome measure was postoperative complications after li
193 The primary
outcome measure was reduction in homeostasis model asses
194 Main
outcome measure was success rate, defined as intraocular
195 The main
outcome measure was surgical failure, defined as patient
196 Primary
outcome measure was surgical success defined in terms of
197 The primary
outcome measure was surgical wound complications.
198 The primary
outcome measure was test positivity rate of SARS-CoV-2 i
199 The primary
outcome measure was the Cambridge Face Memory Test (CFMT
200 The main
outcome measure was the central macular ChT (0.5-mm radi
201 The primary
outcome measure was the change in the average NFL thickn
202 Primary
outcome measure was the change in visual acuity in logMA
203 The primary
outcome measure was the difference between clinical phen
204 The primary
outcome measure was the frequency of adverse events (AEs
205 The primary
outcome measure was the HCV status (antibody and RNA pre
206 The primary
outcome measure was the incidence of hospital readmissio
207 The main
outcome measure was the incremental cost per DALY averte
208 The main
outcome measure was the involvement of the PDL in DMD an
209 An exploratory
outcome measure was the mean number of self-reported ant
210 The primary
outcome measure was the MFIS measured while taking the h
211 The primary
outcome measure was the Montogmery Asberg Depression Rat
212 The secondary
outcome measure was the odds of developing corneal ulcer
213 The primary
outcome measure was the odds ratio (OR) for the associat
214 rgery with IOL implantation, and the primary
outcome measure was the presence or absence of secondary
215 The primary
outcome measure was the proportions of participants who
216 The primary
outcome measure was the rate of surgical failure, define
217 The primary
outcome measure was the RBANS total scale score, with au
218 The
outcome measure was total score reduction from baseline
219 The primary
outcome measure was volumetric MRI percentage brain volu
220 The primary
outcome measured was total antibiotic-days of therapy.
221 The main
outcomes measure was presence of 1 or more postoperative
222 Recurrence-free survival (RFS), the primary
outcome measure,
was evaluated according to Metroticket
223 validation of the pCMT-QOL patient-reported
outcome measure were iterative, involving identifying re
224 The main
outcome measures were (1) the proportion of LTs performe
225 The main
outcome measures were 1) mood, which was assessed by usi
226 Main
outcome measures were 1) occurrence of repeated keratopl
227 The
outcome measures were 1) summary indices of caries exper
228 Primary
outcome measures were 28-day mortality, recurrent stroke
229 The coprimary study
outcome measures were air kerma, dose-area product, fluo
230 Survival
outcome measures were analyzed, along with transplant-re
231 The co-primary
outcome measures were assessor rated symptom severity on
232 Main
outcome measures were average and minimum values of GC-I
233 Outcome measures were best spectacle-corrected visual ac
234 Secondary
outcome measures were best-corrected visual acuity (BCVA
235 Main
outcome measures were best-corrected visual acuity (BCVA
236 The main
outcome measures were best-corrected visual acuity, long
237 Outcome measures were categorized by using the Agency fo
238 Secondary
outcome measures were change in latency to persistent sl
239 The main
outcome measures were change in the percentage of the ch
240 Main
outcome measures were change in visual acuity and the pr
241 The main
outcome measures were changes in BCVA and CMT.
242 Primary
outcome measures were changes in perimetric mean deviati
243 The exploratory
outcome measures were CNV size, IOP and the number of in
244 The primary
outcome measures were confounding factors affecting the
245 All
outcome measures were corrected for age, sex and intracr
246 The main
outcome measures were correlation between percentages of
247 Outcome measures were DE symptoms and signs.
248 Outcome measures were discounted quality-adjusted life-y
249 Associations with
outcome measures were explored in univariate and multiva
250 Maternal
outcome measures were glycaemic control, weight gain, an
251 Primary
outcome measures were graft and patient survival.
252 Main
outcome measures were graft preparation and unfolding ti
253 The main
outcome measures were hospital records of pain, fatigue,
254 Main
outcome measures were incidence of unexpected management
255 The main
outcome measures were incidence, risk factors, predictiv
256 The main
outcome measures were intervention uptake, change in BP,
257 Secondary
outcome measures were intrahepatic lipid (IHL) content,
258 The following secondary IOP
outcome measures were investigated at 12 and 24 months:
259 Outcome measures were itch (presence, chronicity, and in
260 l acuity (BCVA) after nine months, secondary
outcome measures were mean duration of clearance of VH a
261 Primary
outcome measures were mean refracted BCVA and proportion
262 Outcome measures were mood and anxiety disorder health c
263 Outcome measures were overall survival (OS), progression
264 Outcome measures were participation, neoplasia detection
265 The main
outcome measures were perinatal history, visual and neur
266 Main
outcome measures were postoperative intraocular pressure
267 s; and additional access procedures (primary
outcome measures were previously reported).
268 Main
outcome measures were proportion of eyes at 1-year with
269 Main
outcome measures were quality of life (operationalised a
270 Main
outcome measures were regional En/DMT and TCT.
271 The main
outcome measures were resolution of infection, final vis
272 Main
outcome measures were safety, including treatment-emerge
273 Our main
outcome measures were sensitivity, specificity, positive
274 None of the changes in the secondary
outcome measures were significant: rim area, cup volume,
275 Primary
outcome measures were the apnea-hypopnea index (AHI; ie,
276 The primary
outcome measures were the classification accuracy, preci
277 The main
outcome measures were the frequency of and risk factors
278 The main
outcome measures were the incidence of ocular remission,
279 Outcome measures were the incidences of herpes zoster pe
280 Main
outcome measures were the key clinical features, and dis
281 The
outcome measures were the mean spherical equivalent (MSE
282 The primary
outcome measures were the number of colony-forming units
283 The main
outcome measures were the prevalence of LS in an unselec
284 Mental health
outcome measures were the Strengths and Difficulties Que
285 Primary
outcome measures were treatment-emergent AE (TEAE), AESI
286 Other
outcome measures were visit and treatment frequency and
287 Secondary
outcome measures were visual acuity, occurrence of induc
288 The dual primary
outcome measures were worst and average pain scores asse
289 Outcome measures were: (i) Intestinal and renal histopat
290 Outcomes measured were the frequencies of infections and
291 Main
outcomes measured were the MH closure rate assessed by s
292 The primary
outcomes measured were visual acuity, contrast and glare
293 Main
outcomes measured were visual acuity, endothelial cell c
294 The main
outcomes measures were birth before 37 weeks due to spon
295 Main
outcomes measures were the reasons for ICRS removal and
296 al cord blood and, as part of their clinical
outcome measures,
were imaged with diffusion MRI before
297 It may also contribute to defining proper
outcome measures when testing emerging therapies.
298 ular surface severity scores was the primary
outcome measure,
while change in CDVA was the secondary
299 counted for some phenotypic variation in all
outcome measures,
while cage-identity accounted for phen
300 ministration to start of EVT with functional
outcome (measured with the modified Rankin Scale [mRS]),
301 ponse to treatment (ie, number of relapses),
outcomes (measured with the modified Rankin scale [mRS])